NASDAQ:NVTR - Nuvectra Stock Price, Forecast & News

Nuvectra trades on the NASDAQ under the ticker symbol "NVTR."

Nuvectra Corp (NASDAQ:NVTR) issued its quarterly earnings data on Monday, October, 29th. The company reported ($0.87) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.86) by $0.01. The business had revenue of $14.22 million for the quarter, compared to analyst estimates of $12.38 million. Nuvectra had a negative return on equity of 58.23% and a negative net margin of 99.08%. View Nuvectra's Earnings History.

3 analysts have issued 1 year price targets for Nuvectra's stock. Their forecasts range from $4.00 to $18.00. On average, they expect Nuvectra's share price to reach $10.67 in the next twelve months. This suggests a possible upside of 8,105.1% from the stock's current price. View Analyst Price Targets for Nuvectra.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvectra in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nuvectra.

News headlines about NVTR stock have trended negative on Thursday, according to InfoTrie. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nuvectra earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Nuvectra.

Some companies that are related to Nuvectra include Lianluo Smart (LLIT), Hancock Jaffe Laboratories (HJLI), Dynatronics (DYNT), Encision (ECIA), CELLECT BIOTECH/S (APOP), Neurometrix (NURO), Sintx Technologies (SINT), Calmare Therapeutics (CTTC), AdvanSource Biomaterials Corpration (ASNB), Invivo Therapeutics (NVIV), United American Healthcare (UAHC), Regenicin (RGIN), Cytocore (MDIT), Hypertension Diagnostics (HDII) and Delcath Systems (DCTH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Nuvectra investors own include Allena Pharmaceuticals (ALNA), NovaBay Pharmaceuticals (NBY), Avinger (AVGR), Biocept (BIOC), Deciphera Pharmaceuticals (DCPH), Fate Therapeutics (FATE), Iovance Biotherapeutics (IOVA), Rigel Pharmaceuticals (RIGL), Ampliphi Biosciences (APHB) and Arbutus Biopharma (ABUS).

Nuvectra's stock is owned by many different of retail and institutional investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (1.40%), Gabelli Funds LLC (1.18%), Essex Investment Management Co. LLC (0.91%), Gamco Investors INC. ET AL (0.59%), Edge Wealth Management LLC (0.28%) and Millennium Management LLC (0.15%). Company insiders that own Nuvectra stock include Benjamin Tranchina, David D Johnson, Joseph Paul Hanchin and Thomas Edward Zelibor. View Institutional Ownership Trends for Nuvectra.

NVTR stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Millennium Management LLC, Essex Investment Management Co. LLC and SG Americas Securities LLC. View Insider Buying and Selling for Nuvectra.

NVTR stock was bought by a variety of institutional investors in the last quarter, including Gabelli Funds LLC, Gamco Investors INC. ET AL, Valeo Financial Advisors LLC and Edge Wealth Management LLC. Company insiders that have bought Nuvectra stock in the last two years include Benjamin Tranchina, David D Johnson and Thomas Edward Zelibor. View Insider Buying and Selling for Nuvectra.

Shares of NVTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVTR stock can currently be purchased for approximately $0.13.

Nuvectra has a market capitalization of $2.33 million and generates $48.83 million in revenue each year. The company earns $-48,130,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Nuvectra employs 197 workers across the globe.View Additional Information About Nuvectra.

The official website for Nuvectra is http://www.nuvectramed.com/.

Nuvectra's mailing address is 5830 GRANITE PKWY SUITE 1100, PLANO TX, 75024. The company can be reached via phone at 214-474-3103 or via email at [email protected]